HAYWARD, Calif., Jan. 25, 2017 /PRNewswire/ -- Impax
Laboratories, Inc. (NASDAQ: IPXL) announced today that the
Company will release its fourth quarter and full year 2016
financial results on Wednesday, March 1,
2017, prior to the open of the U.S. financial markets. The
Company will host a conference call and live webcast with the
investment community at 8:30 a.m., Eastern
Time on March 1,
2017.
The financial results and live webcast will be accessible
through the Investor Relations section of the Company's Web site at
http://investors.impaxlabs.com.
To access the call through a conference line, dial (877)
356-3814 (in the U.S.) and (706) 758-0033 (international callers).
The conference ID is 58242935.
A replay of the conference call will be available for seven days
shortly after the call. To access the replay, dial (855) 859-2056
(in the U.S.) and (404) 537-3406 (international callers). The
access code for the replay is 58242935.
About Impax Laboratories, Inc.
Impax Laboratories,
Inc. (Impax) is a specialty pharmaceutical company applying
its formulation expertise and drug delivery technology to the
development of controlled-release and specialty generics in
addition to the development of central nervous system disorder
branded products. Impax markets its generic products
through its Impax Generics division and markets its branded
products through the Impax Specialty Pharma division.
Additionally, where strategically appropriate, Impax develops
marketing partnerships to fully leverage its technology platform
and pursues partnership opportunities that offer alternative dosage
form technologies, such as injectables, nasal sprays, inhalers,
patches, creams and ointments. For more information, please visit
the Company's Web site at: www.impaxlabs.com.
Company Contact:
Mark
Donohue
Investor Relations and Corporate Communications
(215) 558-4526
www.impaxlabs.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/impax-to-report-fourth-quarter-and-full-year-2016-results-on-march-1-2017-300396200.html
SOURCE Impax Laboratories, Inc.